Search for Predictors of Therapeutic Response in Ovarian Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

107 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response

NCT03831230

Ovarian Cancer

COMPLETED

Genomic BRCA and Extensive ovArian Cancer Testing

NCT04027868

Epithelial Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer

COMPLETED

Pharmacogenomics of Paclitaxel in Ovarian Cancer

NCT00415181

Ovarian Neoplasms Fallopian Tube Neoplasms

COMPLETED

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients

NCT04152941

Relapsed Ovarian Cancers Patients

COMPLETED

Study of Predictive Factors of Chemoresistance in Ovarian Cancer

NCT02878122

Ovarian Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma of the Ovary Fallopian Tube Cancer Peritoneal Serous-type Advanced Stage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Taxol and carboplatin

blood samples in patients receiving Taxol and carboplatin chemotherapy

Group Type OTHER

blood samples

Intervention Type OTHER

blood samples in patients receiving Taxol and carboplatin chemotherapy :

* On Day 1 of the first course of chemotherapy
* On Day 1 of the second course of chemotherapy
* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
* At the end of chemotherapy

Taxol, carboplatin and avastin

blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin

Group Type OTHER

blood samples

Intervention Type OTHER

blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:

* On Day 1 of the first course of chemotherapy
* On Day 1 of the second course of chemotherapy
* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
* At the end of chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood samples

blood samples in patients receiving Taxol and carboplatin chemotherapy :

* On Day 1 of the first course of chemotherapy
* On Day 1 of the second course of chemotherapy
* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
* At the end of chemotherapy

Intervention Type OTHER

blood samples

blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:

* On Day 1 of the first course of chemotherapy
* On Day 1 of the second course of chemotherapy
* Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
* At the end of chemotherapy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with cancer of the ovary, peritoneum or of the fallopian tube
* Stage III or IV
* Cancer of serous histology
* Patients of any chemotherapy naive
* Patients should receive treatment with chemotherapy for first line by Taxol- Carboplatin. Avastin is authorized in concomitant.
* An initial surgery or through authorized
* Patients who signed informed consent
* Patients over the age of 18 years

Exclusion Criteria

* Patients being treated for another cancer chemotherapy and / or hormone therapy
* Patients receiving other chemotherapy Taxol-carboplatin associated or not to avastin
* Patients under guardianship
* Previous history of pelvic radiotherapy
* History of malignancy blood

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No